Literature DB >> 8241345

Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS).

A Neubauer1, C Brendel, D Vogel, C A Schmidt, I Heide, D Huhn.   

Abstract

p53 is one of the most frequently mutated genes in human cancers. Since p53 has been implicated in lymphatic and some myeloid leukemias, such as the blastic phase of chronic myelogenous leukemia, we sought to address the role of p53 gene mutations within exons 4-9 in myelodysplastic syndromes (MDS), a myeloid preleukemic condition. In order to avoid the potential hazard of using radioactive single-strand conformation analysis (SSCP), we used a nonradioactive SSCP method based on the silver stain of small minigels. In cell lines with known point mutations of the p53 gene, aberrant migrating bands were found. Serial dilutions indicated a sensitivity comparable to radioactive methods. Furthermore, a common polymorphism within the 4th exon of the p53 gene was easily detected. However, of 17 primary samples from patients with MDS, none harbored a p53 gene mutation. We conclude that this nonradioactive method can easily be used to screen for p53-gene mutations, and that p53-gene mutations do not play a major role in the pathogenesis of MDS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241345     DOI: 10.1007/bf01715051

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  23 in total

1.  Non-radioactive single strand conformation polymorphism (SSCP) using the Pharmacia 'PhastSystem'.

Authors:  A J Mohabeer; A L Hiti; W J Martin
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

3.  Frequent mutations in the p53 gene in human myeloid leukemia cell lines.

Authors:  K Sugimoto; H Toyoshima; R Sakai; K Miyagawa; K Hagiwara; F Ishikawa; F Takaku; Y Yazaki; H Hirai
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

4.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

5.  Mutations of the P53 gene in acute myeloid leukaemia.

Authors:  P Fenaux; C Preudhomme; I Quiquandon; P Jonveaux; J L Laï; M Vanrumbeke; M H Loucheux-Lefebvre; F Bauters; R Berger; J P Kerckaert
Journal:  Br J Haematol       Date:  1992-02       Impact factor: 6.998

6.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

7.  Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.

Authors:  J Cheng; M Haas
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

Review 8.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

9.  Mutations in the p53 gene in myelodysplastic syndromes.

Authors:  P Jonveaux; P Fenaux; I Quiquandon; J M Pignon; J L Laï; M H Loucheux-Lefebvre; M Goossens; F Bauters; R Berger
Journal:  Oncogene       Date:  1991-12       Impact factor: 9.867

10.  Alterations of the P53 gene are associated with the progression of a human prostate carcinoma.

Authors:  P J Effert; A Neubauer; P J Walther; E T Liu
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

View more
  1 in total

1.  Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis.

Authors:  M Kikukawa; N Aoki; Y Sakamoto; M Mori
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.